BioXcel Therapeutics (BTAI) announced the advancement of its commercial planning for IGALMI in the at-home setting. As part of this, Mark Pavao has joined as Acting Chief Commercial Officer, CCO, and will lead the development and execution of the Company’s commercial plans. The Company plans to submit a supplemental New Drug Application this month seeking the FDA’s approval of IGALMI for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI: